相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
Julius L. Katzmann et al.
CLINICAL RESEARCH IN CARDIOLOGY (2022)
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2022)
Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? Results from the DA VINCI study
Peter Siostrzonek et al.
WIENER KLINISCHE WOCHENSCHRIFT (2022)
Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study
Philippe van de Borne et al.
ACTA CARDIOLOGICA (2022)
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk
Julius L. Katzmann et al.
PLOS ONE (2022)
Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease
Laura H. Gunn et al.
ATHEROSCLEROSIS PLUS (2022)
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance
Stephen J. Nicholls et al.
AMERICAN HEART JOURNAL (2021)
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
Maurizio Averna et al.
ATHEROSCLEROSIS (2021)
Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort
Christopher Blaum et al.
CLINICAL THERAPEUTICS (2021)
Lipid management across Europe in the real-world setting: a rapid evidence review
Vivencio Barrios et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe-Methodology and rationale for the multinational observational SANTORINI study
Kausik K. Ray et al.
ATHEROSCLEROSIS PLUS (2021)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
Kausik K. Ray et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
Christie M. Ballantyne et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study
Ali Allahyari et al.
EUROPEAN HEART JOURNAL (2020)
Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry
Leonardo De Luca et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2020)
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial
Anne C. Goldberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Christie M. Ballantyne et al.
ATHEROSCLEROSIS (2018)
Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins
Kathleen M. Fox et al.
CLINICAL RESEARCH IN CARDIOLOGY (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
Christopher P. Cannon et al.
JAMA CARDIOLOGY (2017)
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2016)
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk
Enrico Agabiti Rosei et al.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2016)
Variability of the LDL-C lowering response to ezetimibe and ezetimibe plus statin therapy in hypercholesterolemic patients
Olivier Descamps et al.
ATHEROSCLEROSIS (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mendelian randomization of blood lipids for coronary heart disease
Michael V. Holmes et al.
EUROPEAN HEART JOURNAL (2015)
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials
Doralisa Morrone et al.
ATHEROSCLEROSIS (2012)
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials
A. Pandor et al.
JOURNAL OF INTERNAL MEDICINE (2009)
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
MR Law et al.
BRITISH MEDICAL JOURNAL (2003)
分享论文
